Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Randomized Open Label Study Between Once-every-two-weeks and Once-every-four-weeks Treatment of CGC-11047 in Patients With CNV Due to Age Related Macular Degeneration

NCT00446654 is registered in ClinicalTrials.gov with Progen Pharmaceuticals as lead sponsor.

NCT NCT00446654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00446654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Randomized Open Label Study Between Once-every-two-weeks and Once-every-four-weeks Treatment of CGC-11047 in Patients With CNV Due to Age Related Macular Degeneration
Lead sponsor
Progen Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2007
Completion date
October 31, 2007
Enrollment
43 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration